Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre,1 Aurélie Maran-Gonzalez,2 Marie Viala,1 Nelly Firmin,1 Véronique D’Hondt,1,3,4 Marian Gutowski,5 Céline Bourgier,3,6 William Jacot,1,3,4 Séverine Guiu1,3,4 1Department of Medical Oncology, Institut Régional du Cancer d...
Main Authors: | Alexandre M, Maran-Gonzalez A, Viala M, Firmin N, D'Hondt V, Gutowski M, Bourgier C, Jacot W, Guiu S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-12-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/decision-of-adjuvant-systemic-treatment-in-hr-her2--early-invasive-bre-peer-reviewed-article-CMAR |
Similar Items
-
A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy
by: Elodie Chartron, et al.
Published: (2021-12-01) -
RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
by: Haibo Wang, et al.
Published: (2022-12-01) -
Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database
by: Guangfu Hu, et al.
Published: (2020-02-01) -
Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01) -
Current Situation of Postoperative Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma
by: YANG Xiao, et al.
Published: (2023-01-01)